Active, not recruiting
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
NCT06647732
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University Guangzhou, Guangdong, China